Temperature-sensitive liposome wrapping Wnt10b protein as well as preparation method and application of temperature-sensitive liposome

By loading ICG and Fe3O4 NPs on the liposome carrier, the formation of temperature-sensitive liposomes can be achieved, and the photothermal controlled release and magnetic targeted delivery of Wnt10b protein is solved, and the stability and delivery of Wnt10b protein in vivo is improved. The therapeutic effect is achieved and its transport and metabolism in vivo is monitored by multimodal imaging.

CN119015228APending Publication Date: 2024-11-26TIANJIN MEDICAL UNIVERSITY GENERAL HOSPITAL
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411159441.6
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-22
Publication Date
2024-11-26

AI Technical Summary

Technical Problem

The Wnt10b protein has poor stability and is difficult to ensure effective delivery and release in the body, resulting in poor therapeutic effects, and existing liposomes are difficult to achieve targeted delivery and controlled release, resulting in weakening of non-target side effects and therapeutic effects, and lack of effectiveness. imaging monitoring.

Method used

Using a liposome carrier with temperature-sensitive properties and photothermal responsiveness, the temperature-sensitive liposomes wrapped in Wnt10b protein are formed by loading ICG and Fe3O4 NPs, achieving photothermal controlled release and magnetic targeted delivery, and combining fluorescence. and MRI imaging to achieve multi-channel visual monitoring.

Benefits of technology

It improves the bioavailability of Wnt10b protein and the accumulation time of target sites, reduces side effects, enhances the therapeutic effect, and understands the transportation and metabolism of liposomes in the body through multimodal imaging monitoring.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119015228A_ABST
    Figure CN119015228A_ABST
Patent Text Reader

Abstract

The invention provides a thermo-sensitive liposome wrapping Wnt10b protein as well as a preparation method and application of the thermo-sensitive liposome. The liposome is adopted to protect the Wnt10b protein, the Wnt10b protein is isolated from the in-vivo environment of an administration object in the transportation process, the degradation rate of the Wnt10b protein is delayed, and the bioavailability of the Wnt10b protein is improved. Meanwhile, response release of Wnt10b protein is realized through indocyanine green (ICG) on the liposome, and side effects caused by the Wnt10b protein are avoided. Besides, the packaging of the Fe3O4 NPs into the liposome endows the drug delivery system with the characteristics of magnetic targeting and magnetic retention, increases the delivery targeting of the Wnt10b protein, weakens the accumulation of non-target sites and the side effects of the whole body, increases the retention time of the Wnt10b protein at the target site, avoids the dispersion of the Wnt10b protein, and achieves the effect of magnetic retention, thereby enhancing the uptake of the Wnt10b protein by the cells at the target site. Finally, the liposome disclosed by the invention also realizes a bimodal imaging mode by loading a fluorescent dye ICG and a contrast agent Fe3O4NPs.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the field of biomedicine and relates to a liposome, and in particular to a temperature-sensitive liposome encapsulating a Wnt10b protein, and a preparation method and application thereof. Background Art

[0002] Liposomes are tiny vesicle structures composed of a phospholipid bilayer, which are widely used in drug delivery and biomedical research. The basic structure of liposomes is similar to that of cell membranes, with two phospholipid layers surrounding an aqueous cavity. They can encapsulate water-soluble drugs or other bioactive substances, thereby improving the stability and bioavailability of these substances. In water, the hydrophilic head of the phospholipid molecule is inserted into the water, and the hydrophobic tail of the liposome extends into the air. After stirring, a spherical liposome with a double layer of lipid molecules is formed, with a diameter ranging from 25 to 1000nm. Liposomes can be used for genetic modification or prepared drugs, and the characteristics of liposomes that can fuse with cell membranes can be used to deliver drugs into cells.

[0003] Wnt10b protein can stimulate the reconstruction of collagen in damaged areas through the classical Wnt signaling pathway, inhibit the occurrence of fat infiltration, increase the growth of tendon cells, and promote the repair of damaged areas. However, preclinical studies have found that Wnt10b protein has poor stability and is easily decomposed. Since Wnt10b protein is a hydrophobic glycoprotein and is unstable in a serum-free state, it is not easy to ensure protein activity during use. It requires large-dose injection or delivery with the aid of drug carriers such as liposomes to protect Wnt10b before it enters the cell.

[0004] Simple drug delivery carriers cannot achieve targeted drug delivery or drug retention, nor can they control the release and onset of Wnt10b in the body. However, Wnt10b protein has a wide range of biological activities, and the accumulation of Wnt10b protein in non-target sites may lead to a variety of systemic adverse effects such as ectopic bone hyperplasia and ectopic tumors. At the same time, the drug concentration in the target site is greatly reduced, the drug residence time is reduced, and the therapeutic effect is weakened. At the same time, stimulus-responsive controlled release at the target site can also more effectively improve the utilization rate of the drug and the total amount of drug carried in a single dose, thereby reducing the pain and burden on patients due to the need for repeated injections of drugs in clinical practice.

[0005] Liposomes alone are not enough to help researchers or medical staff understand the transport and metabolism of the drug in the body in detail, and single signal monitoring such as bioluminescence imaging or nuclear magnetic resonance imaging has obvious defects. Therefore, it is necessary to use a variety of contrast agents to achieve multi-channel visual monitoring of the distribution and metabolism of the drug delivery system in the body. Summary of the invention

[0006] In view of the deficiencies in the prior art, the object of the present invention is to provide a thermosensitive liposome encapsulating Wnt10b protein, a preparation method and application thereof.

[0007] In the first aspect of the present invention, a method for preparing a thermosensitive liposome encapsulating Wnt10b protein is provided, characterized in that it includes loading the Wnt10b protein on a liposome carrier having thermosensitive properties and photothermal responsiveness to form a thermosensitive liposome encapsulating the Wnt10b protein, wherein the carrier contains ICG (indocyanine green).

[0008] Furthermore, the method specifically includes the following steps:

[0009] Step 1: First, DPPC (dipalmitoylphosphatidylcholine) and Chol (cholesterol) are dissolved in chloroform, and then ICG (indocyanine green) solution with chloroform as solvent is added; after mixing, ultrasonic treatment is performed using a water bath sonicator to form an emulsion, and the emulsion is poured into a light-proof container to avoid quenching of ICG.

[0010] Step 2: Rotate the container containing the emulsion in a water bath to remove the solvent methyl chloride. When there is no remaining liquid in the container, remove it from the rotary evaporator. To prevent the liposome membrane attached to the container wall from being oxidized, the container mouth after rotary evaporation needs to be sealed.

[0011] Step 3: Dissolve Wnt10b protein in PBS and mix to prepare Wnt10b PBS solution; add Wnt10b PBS solution to the film (liposome membrane), and perform ultrasonic treatment using a water bath sonicator; and then perform ultrasonic treatment using an ultrasonic disruptor at reduced power to reduce the particle size.

[0012] Step 4: Then use a liposome extruder to extrude the solution obtained in step 3 back and forth using a filter membrane to further reduce the particle size; then filter the obtained solution through a cellulose acetate membrane to remove impurities mixed into the solution during the operation steps. Finally, add the obtained product to a sucrose solution and freeze-dry to obtain the material Wnt10b-ICG-Liposome; the above operations must be protected from light throughout.

[0013] Furthermore, the concentration of the ICG solution in step 1 is 0.5-0.8 mg / mL, preferably 0.66 mg / mL.

[0014] Furthermore, in step 1, the total power of the ultrasonic treatment is 130-170 W, preferably 150 W; the temperature of the ultrasonic treatment is 3-5° C., preferably 4° C.; and the time of the ultrasonic treatment is 2-4 min, preferably 3 min.

[0015] Furthermore, in step 2, the temperature of the water bath is 40-50°C, preferably 45°C.

[0016] Furthermore, the rotary evaporation in step 2 is firstly carried out at a speed of 110-130 rpm (preferably 120 rpm) for 25-35 seconds (preferably 30 seconds), and then at a speed of 50-70 rpm (preferably 60 rpm) for 0.8-1.2 min (preferably 1 min).

[0017] Furthermore, in step 3, the total power of the first ultrasonic treatment is 130-170 W, preferably 150 W; the temperature of the ultrasonic treatment is 3-5° C., preferably 4° C.; and the time of the ultrasonic treatment is 50-70 min, preferably 60 min.

[0018] Furthermore, in step 3, the power of the second ultrasonic treatment is 25% of the power of the first ultrasonic treatment; the time of the ultrasonic treatment is 2-4 minutes, preferably 3 minutes.

[0019] Furthermore, the pore size of the filter membrane in step 4 is 180-220 nm, preferably 200 nm.

[0020] Furthermore, the number of back and forth extrusion in step 4 is 15-25 times, preferably 20 times.

[0021] Furthermore, in step 4, the pore size of the cellulose acetate membrane is 0.4-0.5 μm, preferably 0.45 μm.

[0022] Furthermore, in step 4, the volume ratio of the product to the sucrose solution is 0.8-1.2:1, preferably 1:1.

[0023] Furthermore, the concentration of the sucrose solution in step 4 is 8-12%, preferably 10%.

[0024] In the second aspect of the present invention, a method for preparing a thermosensitive liposome encapsulating Wnt10b protein is provided, characterized in that it includes loading (encapsulating) Wnt10b protein and Fe3O4 NPs (ferroferric oxide nanoparticles) on a liposome carrier having thermosensitive properties and photothermal responsiveness to form a thermosensitive liposome encapsulating Wnt10b protein, wherein the carrier contains ICG (indocyanine green).

[0025] Furthermore, the method specifically includes the following steps:

[0026] Step 1: First, DPPC (dipalmitoylphosphatidylcholine) and Chol (cholesterol) are dissolved in chloroform, and then ICG (indocyanine green) solution with chloroform as solvent is added; after mixing, ultrasonic treatment is performed using a water bath sonicator to form an emulsion, and the emulsion is poured into a light-proof container to avoid quenching of ICG.

[0027] Step 2: Rotate the container containing the emulsion in a water bath to remove the solvent methyl chloride. When there is no remaining liquid in the container, remove it from the rotary evaporator. To prevent the liposome membrane attached to the container wall from being oxidized, the container mouth after rotary evaporation needs to be sealed.

[0028] Step 3: Wnt10b was dissolved in PBS to prepare Wnt10b PBS solution; Fe3O4 PBS solution was mixed by water bath sonication and then added to the film (liposome membrane) together with Wnt10b PBS solution for hydration; ultrasonic treatment was performed using a water bath sonicator; and ultrasonic treatment was performed using an ultrasonic crusher at reduced power to reduce the particle size.

[0029] Step 4: Then use a liposome extruder to extrude the solution obtained in step 3 back and forth using a filter membrane to further reduce the particle size; then filter the resulting solution through a cellulose acetate membrane to remove impurities mixed into the solution during the operation steps. Finally, add the resulting product to a sucrose solution and freeze-dry to obtain the material Wnt10b-Fe3O4-ICG-LIP. The above operations must be protected from light throughout.

[0030] Furthermore, the concentration of the ICG solution in step 1 is 0.5-0.8 mg / mL, preferably 0.66 mg / mL.

[0031] Furthermore, in step 1, the total power of the ultrasonic treatment is 130-170 W, preferably 150 W; the temperature of the ultrasonic treatment is 3-5° C., preferably 4° C.; and the time of the ultrasonic treatment is 2-4 min, preferably 3 min.

[0032] Furthermore, in step 2, the temperature of the water bath is 40-50°C, preferably 45°C.

[0033] Furthermore, the rotary evaporation in step 2 is firstly carried out at a speed of 110-130 rpm (preferably 120 rpm) for 25-35 seconds (preferably 30 seconds), and then at a speed of 50-70 rpm (preferably 60 rpm) for 0.8-1.2 min (preferably 1 min).

[0034] Furthermore, in step 3, the hydration temperature is 40-50°C, preferably 45°C; the hydration time is 15-25min, preferably 20min.

[0035] Furthermore, in step 3, the total power of the first ultrasonic treatment is 130-170 W, preferably 150 W; the temperature of the ultrasonic treatment is 3-5° C., preferably 4° C.; and the time of the ultrasonic treatment is 4-6 min, preferably 5 min.

[0036] Furthermore, in step 3, the power of the second ultrasonic treatment is 25% of the power of the first ultrasonic treatment; the time of the ultrasonic treatment is 2-4 minutes, preferably 3 minutes.

[0037] Furthermore, the pore size of the filter membrane in step 4 is 180-220 nm, preferably 200 nm.

[0038] Furthermore, the number of back and forth extrusion in step 4 is 15-25 times, preferably 20 times.

[0039] Furthermore, in step 4, the pore size of the cellulose acetate membrane is 0.4-0.5 μm, preferably 0.45 μm.

[0040] Furthermore, in step 4, the volume ratio of the product to the sucrose solution is 0.8-1.2:1, preferably 1:1.

[0041] Furthermore, the concentration of the sucrose solution in step 4 is 8-12%, preferably 10%.

[0042] In the third aspect of the present invention, a thermosensitive liposome encapsulating Wnt10b protein is provided, characterized in that it is prepared by the preparation method of the thermosensitive liposome encapsulating Wnt10b protein according to the first aspect of the present invention or the second aspect of the present invention.

[0043] In a fourth aspect of the present invention, there is provided a use of the thermosensitive liposome encapsulating the Wnt10b protein according to the third aspect of the present invention in the preparation of a drug for promoting the repair of damaged parts.

[0044] Furthermore, the drug is a drug capable of achieving photothermal responsive controlled release for promoting the repair of damaged parts.

[0045] Furthermore, the drug is a drug with magnetic targeting and magnetic retention properties for promoting the repair of damaged parts.

[0046] It should be understood that within the scope of the present invention, the above-mentioned technical features of the present invention and the technical features specifically described below (such as embodiments) can be combined with each other to form a new or preferred technical solution. Due to space limitations, they will not be described one by one here.

[0047] Compared with the prior art, the present invention has the following advantages and progress:

[0048] 1) The liposomes of the present invention can protect the Wnt10b protein. Liposomes are a closed vesicle structure composed of a phospholipid bilayer. They have a simple synthesis method, easy surface modification, good biosafety, strong drug loading and release capabilities, and can encapsulate fat-soluble drugs in the phospholipid bilayer and water-soluble drugs in the liposome. Therefore, the present invention uses liposomes to protect the Wnt10b protein, isolates the Wnt10b protein from the internal environment of the subject during transportation, slows down its degradation rate, and improves its bioavailability.

[0049] 2) The present invention achieves responsive release of drugs through indocyanine green (ICG) on liposomes. ICG is a photothermal agent with an absorption band in the 808nm near-infrared light region, which can convert the absorbed light energy into heat energy. Therefore, under the excitation of 808nm near-infrared light, when the ambient temperature reaches or exceeds the phase transition temperature of the liposome (42°C), the liposome membrane transforms from the gel phase to the liquid crystal phase, and the encapsulated Wnt10b protein is released from the liposome, thereby showing the characteristics of photothermal responsive liposome controlled release drugs to control the release amount of Wnt10b protein and avoid its side effects.

[0050] 3) The present invention endows the drug delivery system with the characteristics of magnetic targeting and magnetic retention by encapsulating Fe3O4 NPs into liposomes. Fe3O4 NPs have strong magnetic responsiveness. Under the manipulation of an external magnetic field, the magnetic liposomes loaded with Wnt10b protein are delivered to the target site required for disease treatment, changing the biodistribution of the liposomes to increase the targeting of drug delivery, reduce the accumulation of non-target sites and systemic side effects. At the same time, the drug deposition at the target site is actively enhanced, the retention time of Wnt10b protein at the target site is increased, and its dispersion is avoided, achieving the effect of magnetic retention, thereby enhancing the uptake of Wnt10b protein by cells at the target site.

[0051] 4) The liposomes of the present invention realize a dual-modal imaging mode by loading the fluorescent dye ICG and the contrast agent Fe3O4 NPs, which can integrate structural or functional information from multiple imaging modes. Fluorescence imaging has the advantages of high sensitivity and low spatial resolution, but poor tissue permeability, and can generally only reach the surface. MRI has high spatial resolution and is not limited by tissue penetration ability, but sometimes has low sensitivity. The two imaging modes complement each other and overcome the shortcomings of a single imaging mode, thereby achieving a synergistic effect and more accurate imaging to monitor the dosage and distribution of drugs in the target area in real time, which helps us further understand the transport and metabolism of liposomes in the body. BRIEF DESCRIPTION OF THE DRAWINGS

[0052] The accompanying drawings, which constitute a part of the present invention, are used to provide a further understanding of the present invention. The exemplary embodiments of the present invention and their descriptions are used to explain the present invention and do not constitute improper limitations on the present invention.

[0053] Figure 1 :Wnt10b, Wnt10b-ICG-Liposome, ICG-Liposome (Wnt10b, 0.4μg / mL) 12h, 24h, 48h promoting cell proliferation effect. Each point in the figure is the MTT absorbance signal of different experimental groups at different times. It can be seen that compared with the simple Wnt10b protein, the protein protected by ICG-Liposome can show the cell proliferation effect for a longer time.

[0054] Figure 2 :The results of the photoinduced thermosensitive controlled release ability of Wnt10b-ICG-Liposome under near-infrared light irradiation. The results showed that the constructed protein drug delivery system has obvious sustained release and near-infrared light-induced controlled release effects.

[0055] Figure 3 : Fluorescence imaging of Fe3O4-ICG-Liposome after co-incubation with MC3T3-E1 cells under no magnetic field and static magnetic field stimulation conditions.

[0056] Figure 4 :Wnt10b-Fe3O4-ICG-Liposome promotes the proliferation of MC3T3-E1 cells under the stimulation of no magnetic field and static magnetic field.

[0057] Figure 5 : In vitro T2-weighted magnetic resonance imaging response characteristics of Fe3O4-ICG-Liposome.

[0058] Figure 6 :In vitro fluorescence imaging of ICG-Liposome.

[0059] Figure 7 :Distribution of fluorescence in major organs at different times after injection of the drug delivery system. In the figure, (A), (B), and (C) correspond to the ICG fluorescence intensity of the major organs (heart, liver, spleen, lung, and kidney) of mice at 3h, 6h, and 12h after in vivo injection of Fe3O4-ICG-Liposome, respectively, and (D) to (F) are the fluorescence imaging results of the major organs at the corresponding time points.

[0060] Figure 8: Changes in near-infrared fluorescence imaging of mice in the Fe3O4-ICG-Lip group (left shoulder) and the Fe3O4-ICG-Lip+magnet fixation group (right shoulder) over time (0h, 1h, 3h, 6h, 12h, 24h, 36h, 48h).

[0061] Fig. 9 Male BALB / c mice were injected with PBS or ICG-Liposome (doses: 2 and 20 mg kg -1 ) Blood routine and biochemical indicators at 2, 7 and 14 days after injection, (A) white blood cell count (WBC), (B) lymphocyte count (Lymph), (C) monocyte count (Mon), (D) neutrophil count (Gran), (E) red blood cell (RBC), (F) mean hemoglobin (HGB), (G) mean hemoglobin content (MCH), (H) mean hematocrit (MCV), (I) mean hemoglobin concentration (MCHC), (J) platelet count (PLT), (K) alkaline phosphatase (ALP), (L) alanine aminotransferase (ALT), (M) aspartate aminotransferase (AST), (N) urea (UREA), (O) serum creatinine (CREA), (n=3). The results showed that after injection of the material, all the physical signs of the mice were within the normal range, indicating that the material did not affect the coagulation system and liver and kidney functions of the mice.

[0062] Fig.10 :HE staining results at different time points after injection of different concentrations of Fe3O4-ICG-Liposome. By collecting pathological sections of the main organs of mice (heart, liver, spleen, lung, and kidney) and comparing the staining results with the control group, it can be found that there is no significant difference between the two, indicating that the material has no effect on the main organs of mice. DETAILED DESCRIPTION

[0063] The present invention provides a thermosensitive liposome encapsulating Wnt10b protein, a preparation method and application thereof. The present invention is specifically described below in conjunction with the embodiments to facilitate further understanding of the present invention by those skilled in the art. However, the embodiments described below are only part of the embodiments of the present invention and should not be regarded as any form of limitation to the present invention. It should be pointed out that adjustments and improvements made by ordinary technicians in this field based on the concept of the present invention should be regarded as the scope of protection of the present invention. The specific technical operation steps and operators are not indicated in the embodiments, and they are all carried out according to the general technical conditions described in the literature of the field or the relevant product instructions.

[0064] Example 1 Preparation of liposomes

[0065] ① Synthesis of ICG-modified thermosensitive liposomes (ICG-Liposome) by thin film hydration method:

[0066] Step 1: First, weigh 16 mg DPPC and 4 mg Chol and dissolve them in 2.5 mL methyl chloride, then add 0.66 mg / mL ICG in 1 mL methyl chloride as solvent. After mixing, use a water bath sonicator with a total power of 150 W and sonicate at 4°C for 3 min to form an emulsion, pour the emulsion into a round-bottom flask, and wrap the round-bottom flask with tin foil to avoid light to prevent ICG quenching.

[0067] Step 2: Place the round-bottom flask containing the emulsion in a 45°C water bath and perform rotary evaporation at 120 rpm for 30 seconds, then at 60 rpm for 1 minute to remove the solvent methyl chloride. When there is no remaining liquid in the flask, remove it from the rotary evaporator. To prevent the liposome membrane attached to the flask wall from being oxidized, the mouth of the flask after rotary evaporation needs to be sealed.

[0068] Step 3: Add 10 mL of PBS solution to the flask after rotary evaporation, and use a water bath sonicator with a total power of 150 W at 4° C. for 5 min. Then use an ultrasonic crusher with a power of 25% for 3 min to reduce the particle size.

[0069] Step 4: Then use a liposome extruder and use a 200nm filter membrane to extrude the solution obtained in the previous step back and forth 20 times to further reduce the particle size. Then filter the resulting solution through a cellulose acetate membrane with a pore size of 0.45μm to remove impurities mixed into the solution during the operation steps. Finally, add 10% sucrose solution to the resulting product at a ratio of 1:1 (volume ratio) and freeze-dry to obtain the material ICG-Liposome. The above operations must be protected from light throughout the process.

[0070] ② The ICG-modified Wnt10b-coated thermosensitive liposomes (Wnt10b-ICG-Liposome) were synthesized by thin film hydration method:

[0071] Step 1: Repeat steps 1-2 in ① to prepare liposome film.

[0072] Step 2: Dissolve 20 μg of Wnt10b protein in 10 mL of PBS and mix well to prepare Wnt10b PBS solution. Add Wnt10b PBS solution to the film and sonicate at 4°C for 60 min using a water bath sonicator with a total power of 150 W. Then sonicate at 25% power for 3 min using an ultrasonic disruptor to reduce the particle size.

[0073] Step 3: Repeat step 4 in ① to obtain the material Wnt10b-ICG-Liposome.

[0074] ③ Thermosensitive liposomes (Fe3O4-ICG-Lip) loaded with ICG and Fe3O4 were synthesized by thin film hydration method:

[0075] Step 1: Repeat steps 1-2 in ① to prepare liposome film.

[0076] Step 2: Add 10 mL of Fe3O4 solution dissolved in PBS to the flask after rotary evaporation and hydrate at 45°C for 20 minutes. Use a water bath sonicator with a total power of 150W at 4°C for 5 minutes, and then use an ultrasonic crusher with a power of 25% for 3 minutes to reduce the particle size.

[0077] Step 3: Repeat step 4 in ① to obtain the material Fe3O4-ICG-Lip.

[0078] ④ Thermosensitive liposomes (Wnt10b-Fe3O4-ICG-Lip) containing ICG, Fe3O4 and Wnt10b were synthesized by thin film hydration method:

[0079] Step 1: Repeat steps 1-2 in ① to prepare liposome film.

[0080] Step 2: Dissolve 10 mg of Wnt10b in 5 mL of PBS, and then add 5 mL of Fe3O4 PBS solution to the film for hydration at 45°C for 20 min. Use a water bath sonicator with a total power of 150 W at 4°C for 5 min, and then use an ultrasonic crusher with a power of 25% for 3 min to reduce the particle size.

[0081] Step 3: Repeat step 4 in ① to obtain the material Wnt10b-Fe3O4-ICG-LIP.

[0082] Example 2 MTT measurement of the ability of Wnt10b-ICG-Liposome to promote osteoblast proliferation

[0083] Experimental methods:

[0084] ① Experimental groups: blank control group, Wnt10b protein group, ICG-Liposome, and Wnt10b-ICG-Liposome.

[0085] ② Take MC3T3-E1 cells in the logarithmic growth phase and plate them in a 96-well plate at 1000 cells / well.

[0086] ③ Place in a 37°C, 5% CO2 incubator for 12 hours. After the cells adhere to the wall, remove the old culture medium and add 200 μL of complete culture medium, 200 μL of complete culture medium solution of Wnt10b protein (0.4 μg / mL, AtaGenix, catalog number: YA9057H), 200 μL of complete culture medium solution of ICG-Liposome, and 200 μL of complete culture medium solution of Wnt10b-ICG-Liposome (Wnt10b concentration is 0.4 μg / mL) in the protein liposome encapsulation group. Repeat 5 wells for each group.

[0087] ④ After culturing in a 37°C, 5% CO2 incubator for 12h, 24h or 48h, remove the old culture medium, wash twice with PBS, and add 10μL / well of MTT.

[0088] After 4 h, MTT was removed, 150 μL DMSO was added, and after shaking for 10 min, the plate was placed in an ELISA reader to measure the OD value of each well at 570 nm.

[0089] Experimental results:

[0090] The ability of Wnt10b-ICG-Liposome to promote osteoblast growth was tested by MTT. Figure 1 As shown, it can be clearly found that before 24 hours, free Wnt10b protein can promote the growth of osteoblasts better than liposome-encapsulated Wnt10b protein. However, after 48 hours, the effect of liposome-encapsulated Wnt10b protein on the growth of osteoblasts is much higher than that of other groups. This fully demonstrates that liposomes have the function of sustained release of Wnt10b protein, and the osteogenic effect after 48 hours is higher than that of free Wnt10b protein, indicating that more Wnt10b protein is utilized by cells, and liposomes better protect Wnt10b protein, which significantly enhances the stability of Wnt10b.

[0091] Example 3 Photoinduced thermosensitive controlled release ability of Wnt10b-ICG-Liposome under near-infrared light irradiation

[0092] Experimental methods:

[0093] Wnt10b-ICG-Liposome and free Wnt10b were dispersed in 2 mL PBS, respectively, and the above solutions were placed in dialysis bags and sealed, and the dialysis bags were placed in 50 mL PBS. At the predetermined time points of 10 min, 30 min, 1 h, 3 h, 6 h, 12 h, and 24 h, 100 μL of dialysate was collected and supplemented with 100 μL of the same PBS solution. The protein concentration at the above time points was measured using the BCA method.

[0094] Experimental results:

[0095] The photosensitive controlled release ability of liposomes was verified by in vitro simulated drug release experiments. By comparing the release curve of free Wnt10b in 24 hours, it can be seen that Figure 2 It shows that Wnt10b encapsulated in liposomes is released more slowly, and the results indicate that liposomes have better drug preservation ability. In addition, we studied the effect of different temperatures on the release of drugs from ICG-Liposomes. Wnt10b-ICG-Liposomes were dispersed in 2 mL PBS, the above solution was placed in a dialysis bag and sealed, and incubated in a cell culture incubator at 37°C and 42°C for 24 hours, and 100 μL of dialysate was collected at the predetermined time points of 10 min, 30 min, 1 h, 3 h, 6 h, 12 h, and 24 h, and supplemented with 100 μL of the same PBS solution. The results are as follows Figure 2 As shown in (B), the release rate of Wnt10b at 42°C was greatly increased compared to 37°C. In less than 6 hours, the drug release rate reached 90%. This fully demonstrates that the liposomes we synthesized have temperature-sensitive properties. We then studied the effect of laser irradiation on the release of Wnt10b from ICG-Liposomes. Figure 2 (C) As shown in Figure 2, the rate of Wnt10b release from ICG-Liposome after 808nm laser irradiation is higher than that from ICG-Liposome without laser irradiation. The results indicate that the ICG-Liposome synthesized by us can achieve photothermal response release under near-infrared light, and the system has the ability of light-controlled drug release.

[0096] Example 4: Experimental study on cell uptake of drug delivery system driven by magnetic field

[0097] Experimental methods:

[0098] ① Experimental groups: Fe3O4-ICG-Liposome group, Fe3O4-ICG-Liposome magnetic field driven group (Fe3O4-ICG-Liposome+SMF).

[0099] ② Take MC3T3-E1 cells in the logarithmic growth phase and plate them in a 6-well plate at 20,000 cells / well.

[0100] ③ Use DMSO to dissolve Dil to prepare a 5M Dil solution, incubate Fe3O4-ICG-Liposome with the Dil solution at 37°C in the dark for 20 min, centrifuge at 8000 rpm for 5 min, discard the supernatant to remove free Dil dye, resuspend with PBS, and repeat the washing steps twice.

[0101] ④ After 24 hours of plating, the old culture medium was removed and serum-free culture medium and Dil-labeled Fe3O4-ICG-Liposome were added. At the same time, the left side of the well was used as the Fe3O4-ICG-Liposome group; the right side of the well was treated with a magnet and used as the Fe3O4-ICG-Liposome+SMF group.

[0102] ⑤ After 4 hours, add 10% serum to the culture medium, culture in a 37°C, 5% CO2 incubator for 6 hours, and then take out.

[0103] ⑥ Remove the old culture medium and fix the cells with 4% paraformaldehyde for 10 minutes. Wash the cells twice with PBS, 3 minutes each time.

[0104] ⑦ Treat the cells with 0.5% TritonX-100 for 30 seconds to increase cell permeability. Wash the cells with PBS for 5 minutes.

[0105] ⑧ Treat cells with DAPI stain for 10 min. Wash cells twice with PBS, 3 min each time.

[0106] ⑨ Use an inverted fluorescence microscope to adjust the appropriate fluorescence intensity, exposure time, and focal length (first use the coarse focus knob to make a rough adjustment, then use the fine focus knob to make a fine adjustment) and then take pictures.

[0107] Experimental results:

[0108] The cell uptake experiment verifies the magnetic responsiveness of the drug delivery system equipped with Fe3O4-ICG-Liposome. By comparing with the Fe3O4-ICG-Liposome group without magnetic field drive, under magnetic field conditions, the Fe3O4-ICG-Liposome magnetic field driven group clearly showed magnetic targeting enrichment ability. Through cytoscopy observation, it can be found that in the presence of a magnetic field, the Fe3O4-ICG-Liposome (red spot) taken up by cells increased significantly. This phenomenon shows that through the addition of Fe3O4 magnetic nanoparticles, the drug delivery system obviously shows better tissue cell targeting and stronger drug utilization. Specifically, this experiment aims to detect the uptake ability of osteoblasts for Fe3O4-ICG-Liposome under the action of a magnetic field, and verify the magnetic responsiveness of the material. Figure 3 As shown, the Dil-labeled liposomes are around the cell nucleus, indicating that some liposomes have entered the cells, and the uptake of osteoblasts under the static magnetic field is significantly higher than that without the magnetic field, proving that the material has good magnetic responsiveness. The static magnetic field can enrich more liposomes, increase the local liposome concentration, and increase the retention time of liposomes, thereby promoting cell uptake of liposomes.

[0109] Example 5 Experiment on promoting cell proliferation by drug delivery system driven by magnetic field

[0110] Experimental methods:

[0111] ① Experimental groups: blank control group, Wnt10b group, Wnt10b-Fe3O4-ICG-Lip, and Wnt10b-Fe3O4-ICG-Lip+SMF.

[0112] ② Take MC3T3-E1 cells in the logarithmic growth phase and plate them in a 96-well plate at 1000 cells / well.

[0113] ③ Place in a 37°C, 5% CO2 incubator for 12 hours. After the cells adhere to the wall, remove the old culture medium and add 200 μL of complete culture medium to the control group; add 200 μL of complete culture medium solution of Wnt10b-Fe3O4-ICG-Lip (liposome concentration 200 μg / mL) to the other two groups, respectively. The Wnt10b-Fe3O4-ICG-Lip+SMF group was treated with a magnet, and a positive control group (Wnt10b group) with only the same amount of Wnt10b protein was set up separately. Each group was repeated for 5 wells.

[0114] ④ After culturing in a 37°C, 5% CO2 incubator for 4 hours, the culture medium of each group was discarded, 200 μL of complete culture medium was added, PBS was washed three times, and then cultured for 8 hours, 20 hours, 44 hours and 68 hours respectively (the total incubation time of cells and materials was controlled to be 12 hours, 24 hours, 48 ​​hours and 72 hours). Subsequently, the living cells in each well were stained with Green488 live cell nuclear dye, and the cell survival rate of each group was examined by fluorescence analysis.

[0115] Experimental results:

[0116] pass Figure 4The cell survival rate test results shown show that compared with the blank control group without any material or Wnt10b protein treatment, the cell survival rate increased within 48 hours after the addition of Wnt10b, proving that Wnt10b molecules can promote cell growth. We used Fe3O4-ICG-Liposome to load Wnt10b protein, and then applied a magnetic field to the Fe3O4-ICG-Liposome+SMF group during cell culture, so that the material in this group would not be removed by the replacement of the solution 4 hours after incubation, but could continue to reflect the sustained release effect of Wnt10b protein. Comparing the cell survival rate of the Wnt10b-Fe3O4-ICG-Lip+SMF group with that of other groups, it can be found that due to the magnetic enrichment effect of Fe3O4-ICG-Liposome, the Wnt10b protein contained therein can continue to work within 72 hours, while the cell survival rate of other groups has dropped significantly at 72 hours because the Wnt10b protein has been washed away by the replacement of the solution or does not contain Wnt10b protein. This result strongly proves that through the enrichment of Fe3O4-ICG-Liposome under magnetic field conditions, drug molecules can continue to take effect at the target site.

[0117] Example 6 MRI measurement of in vitro magnetic resonance response characteristics of Fe3O4-ICG-Liposome

[0118] Experimental methods:

[0119] Fe3O4-ICG-Liposome was prepared into a 0-0.16 mM (concentration in terms of Fe ions) aqueous solution and neatly placed on a test tube rack. A T2-weighted MRI was performed using a magnetic resonance imaging device, and its T2 value was recorded. A linear graph was drawn with 1 / T2 value as the ordinate and Fe ion concentration as the abscissa to calculate the relaxation rate of Fe3O4-ICG-Liposome.

[0120] Experimental results:

[0121] The in vitro magnetic resonance response characteristics of Fe3O4-ICG-Liposome were studied by in vitro MRI. Figure 5 It can be seen that as the Fe ion concentration gradually increases, the T2 signal intensity gradually decreases, which is reflected in the image as the magnetic resonance imaging image gradually becomes darker. 1 / T2 has a good linear relationship with the Fe ion concentration, and the calculated transverse relaxation rate (r2) is 35.36mM -1 S -1 (i.e. the slope of the straight line), indicating that the Fe3O4-ICG-Liposome carrier has good in vitro magnetic response properties and can be used as an in vitro T2-type MRI contrast imaging contrast agent.

[0122] Example 7 IVIS measurement of ICG-Liposome fluorescence imaging effect

[0123] Experimental methods:

[0124] ICG-Liposome was prepared into PBS solutions of 62.50, 31.25, 15.63, 7.81, and 3.91 μg / mL (the concentration was based on the ICG concentration in ICG-Liposome), and added to a 24-well plate. Fluorescence imaging was performed using an IVIS imaging system, and the total radiant efficiency (Total Radiant Efficiency) was recorded.

[0125] Experimental results:

[0126] The fluorescence imaging properties of ICG-Liposome were measured using IVIS. Figure 6 As shown, with the increase of ICG concentration, the total radiation efficiency gradually increased, and the fluorescence signal in the image was strengthened accordingly, indicating that the ICG-Liposome carrier has a good fluorescence imaging effect and can be used for IVIS imaging.

[0127] Example 8 Fluorescence distribution of major organs at different times after injection of drug delivery system

[0128] Experimental methods:

[0129] ① Weigh the body weight of 8-week-old BALB / c male mice.

[0130] ② Inject 150 μL ICG-Liposome (2 mg kg -1 ), PBS, 9 mice in each group.

[0131] ③ Set the time points of 3h, 6h, and 12h, and kill the mice by cervical dislocation (breaking the neck), with 3 mice at each time point.

[0133] ④Dissect the mouse, collect the heart, liver, spleen, lung and kidney of the mouse, and use the mouse in vivo imaging device for imaging. Set the excitation wavelength to 745nm and the imaging agent to ICG.

[0134] ⑤ Collect the average fluorescence intensity values ​​of the mouse heart, liver, spleen, lungs and kidneys after imaging.

[0135] Experimental results:

[0136] Depend on Figure 7It can be seen that after the injection of ICG-Liposome, the fluorescence signal of the liver was significantly stronger than that of other organs at each time point. This proves that ICG-Liposome is mainly enriched in the liver in mice, and the signal of the liver can better reflect the metabolism of liposomes in the body. As time goes by, the liver signal is consistent with the control group after 12 hours, indicating that the liposomes have been completely metabolized or excreted from the body after 12 hours.

[0137] Example 9 IVIS verification of the in vivo metabolism and distribution of Fe3O4-ICG-Lip driven by magnetic field

[0138] Experimental methods:

[0139] ① Weigh the body weight of 8-week-old BALB / c male mice.

[0140] ② Inject 50 μL Fe3O4-ICG-Lip (20 mg / kg) into the left and right shoulders of mice according to their body weight, and treat the right shoulder with a magnet.

[0141] ③ Set the time points of 0h, 1h, 3h, 6h, 12h, 24h, 36h, and 48h, and use the mouse living imager to image the mice after anesthesia, and observe the changes of near-infrared fluorescence imaging of mice in the Fe3O4-ICG-Lip group (left shoulder) and Fe3O4-ICG-Lip + magnet fixation group (right shoulder) over time (0h, 1h, 3h, 6h, 12h, 24h, 36h, 48h).

[0142] Experimental results:

[0143] Depend on Figure 8 The results show that compared with the Control group, after the Fe3O4-ICG-Lip material was injected into both shoulders at the same time, obvious fluorescence signals were detected in both shoulders, and there was no significant difference in fluorescence intensity, proving that the amount of Fe3O4-ICG-Lip material injected into both shoulders was equal. Subsequently, the magnet was fixed on the right shoulder of the mouse for magnetic enrichment, while the left shoulder was not treated in any way, and the changes in the intensity and distribution of fluorescence signals in both shoulders were observed at different time points. One hour after injection, both shoulders still showed strong fluorescence signals, and signals appeared at the right limb end, proving that a small amount of material was enriched in the terminal tissue, but a large amount of material was still enriched in the shoulder; strong signals could be observed in the left shoulder and left forelimb, proving that the material had begun to diffuse under the condition of lack of magnetic field fixation. As time passed, the fluorescence signal could still be observed on the right side at 48 hours, but there was no fluorescence on the left side at 36 hours, proving that our drug delivery material can continue to work within 48 hours under the enrichment of the magnetic field, while the left shoulder was not fixed by the magnetic field, and the retention time of the material was significantly shortened.

[0144] Examples 6-9 verified the magnetic / optical dual-modal imaging capability of the Fe3O4-ICG-Liposome drug delivery system. In order to achieve multi-channel, multi-modal visual monitoring of the distribution and metabolism of the drug delivery system in vivo, the in vitro magnetic resonance response characteristics and fluorescence imaging effects of Fe3O4-ICG-Liposome were investigated respectively. The results show that through the above imaging method, we can investigate the distribution of the Fe3O4-ICG-Liposome drug delivery system in the main organs of mice.

[0145] Example 10 Blood routine and liver and kidney function serum biochemical detection and HE staining

[0146] Experimental methods:

[0147] 1. Blood routine and serum biochemical tests of liver and kidney function

[0148] ① Inject 150 μL ICG-Liposome (2, 20 mg kg -1 ), and the same volume of PBS solution was injected as the control group.

[0149] ② At different times (2, 7, and 14 days), mice were anesthetized with 150 μL of 5% chloral hydrate, and blood was collected from the mice using the eyeball blood collection method. Half of the blood was placed in EDTA anticoagulant tubes for measuring blood routine, and the other half was placed in EP tubes for collecting serum to measure biochemical indicators.

[0150] a) Perform blood routine examination using a whole blood automatic analyzer: Take 200 μL of mouse blood and add it to an EDTA-K2 anticoagulant tube, and use a fully automatic blood cell analyzer to detect blood routine related indicators such as red blood cell, hemoglobin, white blood cell and platelet content.

[0151] b) Use a semi-automatic biochemical analyzer to detect serum biochemical indicators: place the remaining blood at 4°C overnight, wait for the blood to shrink spontaneously, collect the upper serum and perform biochemical indicator detection according to the kit instructions.

[0152] ③ The mice were killed by cervical dislocation (neck breaking), and the heart, liver, spleen, lungs and kidneys were removed by dissection. After taking pictures under bright field, the mice were placed in 10% neutral formalin solution.

[0153] 2. HE staining

[0154] ① Cut the tissue into 5mm×5mm×2mm.

[0155] ②After the material is fixed, rinse it with running water for several hours or overnight.

[0156] ③ The materials were dehydrated in 70%, 80%, and 90% ethanol solutions for 30 min each, and then placed in 95% and 100% ethanol solutions twice, each for 20 min.

[0157] ④ Transparency: Mix equal amounts of pure alcohol and xylene for 15 minutes, xylene I for 15 minutes, and xylene II for 15 minutes (until transparent).

[0158] ⑤ Wax penetration: Put in a mixture of half xylene and half paraffin for 15 minutes, then put in paraffin for 50-60 minutes.

[0159] ⑥ Embedding: Select a suitable embedding mold, inject the melted paraffin from the embedding machine into the embedding mold (metal), clamp the tissue block, place it in the center of the bottom of the embedding mold, and gently flatten it.

[0160] ⑦ Section, spread, mount, dewax and rehydrate.

[0161] ⑧Staining: Place in hematoxylin and stain for about 10-30 minutes.

[0162] ⑨ Washing: Rinse with running water for about 15 minutes to make the slices blue (or put them in alkaline water), but be careful not to run too much water to prevent the slices from falling off.

[0163] ⑩ Differentiation: Place the slices in 1% hydrochloric acid ethanol solution to fade for about 2 seconds to tens of seconds. When the slices turn red and the color becomes lighter, they are ready. Place the slices in running water to restore the blue color.

[0164] Dehydration and restaining: Immerse the sections in 50% ethanol → 70% ethanol → 80% ethanol for 3-5 minutes each, and use 0.5% eosin ethanol solution for counterstaining for 1-3 minutes.

[0165] Dehydration and transparency: Place the slices in 95% ethanol to wash off excess red, and place them in anhydrous ethanol for 3-5 minutes. Finally, use absorbent paper to absorb excess ethanol, and place the slices in xylene I and II for 3-5 minutes each. Finally, use neutral gum to seal the slices and observe under an optical microscope.

[0166] Experimental results:

[0167] The in vivo biosafety of the liposomes was evaluated by blood routine tests, biochemical tests, and HE staining of major organs. Fig. 9 It can be seen that compared with the control group, the mice injected with 2mg / kg and 20mg / kg showed no obvious abnormalities in blood routine, liver and kidney indicators within 2, 7 and 14 days, which indicates that the material does not cause acute and subacute inflammation and liver and kidney damage in mice. Fig.10As shown in the figure, from the morphological observation, the material has no damage to the heart, liver, spleen, lung and kidney of animals in the short or long term within the concentration of 20 mg / kg. Our material has good biocompatibility and biosafety for mice and will not cause acute or subacute damage.

[0168] Specifically, in order to determine whether ICG-Liposome is toxic to the whole body of mice, blood routine test, biochemical routine test, and HE staining were used to observe whether the whole body of mice had lesions from the macroscopic and microscopic perspectives. Fig. 9 It can be seen that compared with the control group, the mice injected with 2mg / kg and 20mg / kg showed no obvious abnormalities in blood routine, liver and kidney indicators within 2, 7 and 14 days, which indicates that the material does not cause inflammation and liver and kidney damage in mice. HE staining results ( Fig.10 ) It can be seen that compared with the control group, at different time points, the myocardial nuclei of mice in the 2mg / kg and 20mg / kg groups were centrally distributed and clear, showing an oval shape, and the myocardial cells were evenly stained, showing a short cylindrical shape, with branches, no cell swelling, and no collagen fiber hyperplasia. The myocardial fibers were arranged neatly. There was no myocardial cell necrosis. The hepatic lobules and portal areas were infiltrated by inflammatory cells, and no degeneration and necrosis occurred; the hepatocyte cords were arranged neatly and radially, and the morphology of the liver parenchyma was regular, without diffuse changes. The spleen corpuscles were not enlarged, the distribution was uniform, and the number of follicles did not increase. There was no inflammatory cell infiltration, and the spleen morphology and structure were normal. The alveolar septa were not significantly widened, no neutrophils or red blood cells were exuded into the alveolar cavity, no inflammatory cell infiltration was around the blood vessels, and the alveolar epithelial cells were arranged regularly, without obvious abnormalities. The renal tubules were not damaged, the renal tubular epithelial cells were normal in morphology, arranged regularly, without obvious shedding, the renal tubular basement membrane was intact, there was no edema in the renal interstitium, and there was no inflammatory cell infiltration. In summary, according to the results of HE, the material has no damage to the heart, liver, spleen, lungs and kidneys of animals in the short or long term within a concentration of 20 mg / kg. Our material has good biocompatibility and biosafety for mice and will not cause acute or subacute damage.

[0169] The above is only a preferred embodiment of the present invention and does not limit the present invention in any way. For those skilled in the art, any modification and change made to the above embodiment according to the technical essence of the present invention shall fall within the protection scope of the technical solution of the present invention.

Claims

1. A method for preparing a thermosensitive liposome encapsulating Wnt10b protein, characterized in that: The method comprises loading the Wnt10b protein onto a liposome carrier having a thermosensitive property and photothermal responsiveness to form a thermosensitive liposome encapsulating the Wnt10b protein, wherein the carrier contains ICG.

2. The method for preparing the thermosensitive liposome encapsulating Wnt10b protein according to claim 1, characterized in that: The specific steps include: Step 1: First, DPPC and Chol are dissolved in methyl chloride, and then an ICG solution with methyl chloride as solvent is added; after mixing, an emulsion is formed by ultrasonic treatment using a water bath sonicator, and the emulsion is poured into a light-proof container to avoid quenching of ICG; Step 2: The container containing the emulsion is subjected to rotary evaporation in a water bath to remove the solvent methyl chloride. When there is no remaining liquid in the container, it is removed from the rotary evaporator. To prevent the liposome membrane attached to the container wall from being oxidized, the container mouth after rotary evaporation needs to be sealed; Step 3: dissolving Wnt10b protein in PBS and mixing to prepare Wnt10b PBS solution; adding Wnt10b PBS solution to the liposome film, and performing ultrasonic treatment using a water bath sonicator; and then performing ultrasonic treatment using an ultrasonic disruptor at reduced power to reduce the particle size; Step 4: Then use a liposome extruder and filter the solution obtained in step 3 back and forth to further reduce the particle size; then filter the obtained solution through a cellulose acetate membrane to remove impurities mixed into the solution during the operation steps; finally, add the obtained product to a sucrose solution and freeze-dry to obtain the material Wnt10b-ICG-Liposome; the above operations must be protected from light throughout.

3. The method for preparing the thermosensitive liposome encapsulating Wnt10b protein according to claim 2, characterized in that: The concentration of the ICG solution in step 1 is 0.5-0.8 mg / mL.

4. A method for preparing a thermosensitive liposome encapsulating Wnt10b protein, characterized in that: The method comprises loading Wnt10b protein and Fe3O4 NPs on a liposome carrier having thermosensitive characteristics and photothermal responsiveness to form a thermosensitive liposome encapsulating the Wnt10b protein, wherein the carrier contains ICG.

5. The method for preparing the thermosensitive liposome encapsulating Wnt10b protein according to claim 4, characterized in that: The specific steps include: Step 1: First, DPPC and Chol are dissolved in methyl chloride, and then an ICG solution with methyl chloride as solvent is added; after mixing, an emulsion is formed by ultrasonic treatment using a water bath sonicator, and the emulsion is poured into a light-proof container to avoid quenching of ICG; Step 2: The container containing the emulsion is subjected to rotary evaporation in a water bath to remove the solvent methyl chloride. When there is no remaining liquid in the container, it is removed from the rotary evaporator. To prevent the liposome membrane attached to the container wall from being oxidized, the container mouth after rotary evaporation needs to be sealed; Step 3: Wnt10b is dissolved in PBS to prepare a Wnt10b PBS solution; Fe3O4 PBS solution is mixed by water bath sonication and then added to the liposome film together with the Wnt10b PBS solution for hydration; ultrasonic treatment is performed using a water bath sonicator; and ultrasonic treatment is performed using an ultrasonic crusher at a reduced power to reduce the particle size; Step 4: Then use a liposome extruder and filter the solution obtained in step 3 back and forth to further reduce the particle size; then filter the obtained solution through a cellulose acetate membrane to remove impurities mixed into the solution during the operation steps; finally, add the obtained product to a sucrose solution and freeze-dry to obtain the material Wnt10b-Fe3O4-ICG-LIP; the above operations must be protected from light throughout.

6. The method for preparing the thermosensitive liposome encapsulating Wnt10b protein according to claim 5, characterized in that: The concentration of the ICG solution in step 1 is 0.5-0.8 mg / mL.

7. A thermosensitive liposome encapsulating Wnt10b protein, characterized in that: The liposome is prepared by the method for preparing the thermosensitive liposome encapsulating the Wnt10b protein according to any one of claims 1 to 6.

8. Use of the thermosensitive liposome encapsulating the Wnt10b protein according to claim 7 in the preparation of a drug for promoting the repair of damaged parts.

9. The use according to claim 8, characterized in that: The drug is a drug capable of achieving photothermal responsive controlled release and is used to promote the repair of damaged parts.

10. The use according to claim 8, characterized in that: The drug is a drug with magnetic targeting and magnetic retention properties and is used for promoting the repair of damaged parts.